Influenza virus H9N2 vaccine - Crucell
Latest Information Update: 03 Dec 2012
At a glance
- Originator Crucell
- Class Influenza A vaccines
- Mechanism of Action Immunostimulants
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- No development reported Influenza A virus H9N2 subtype